Rosuvastatin reduces nonalcoholic fatty liver disease in patients with chronic hepatitis C treated with α-interferon and ribavirin: Rosuvastatin reduces NAFLD in HCV patients

BACKGROUND: Nonalcoholic fatty liver disease develops in patients with chronic hepatitis C. Interferon and ribavirin combination therapy is the standard treatment for chronic hepatitis C, but if present, NAFLD can reduce the virological response to anti-HCV therapies. OBJECTIVES: We determined wheth...

Descripción completa

Detalles Bibliográficos
Autores principales: Malaguarnera, Michele, Vacante, Marco, Russo, Cristina, Gargante, Maria Pia, Giordano, Maria, Bertino, Gaetano, Neri, Sergio, Malaguarnera, Mariano, Galvano, Fabio, Volti, Giovanni Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kowsar 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3206670/
https://www.ncbi.nlm.nih.gov/pubmed/22087124

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3206670/
https://www.ncbi.nlm.nih.gov/pubmed/22087124

Ejemplares similares